{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-220671","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2026-05-13T12:15:06+00:00","discovered_at":"2026-05-13T12:20:00.347029+00:00","generated_at":"2026-05-13T12:23:36.871699+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"ARS Pharma appoints Donn Casale as President effective June 1, 2026","bullets":["Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.","Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.","Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.","Option vests 25% after one year, then monthly over 36 months; subject to continued employment.","He replaces Richard Lowenthal as President; Lowenthal remains CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-220671","json":"https://secwatch.observer/filing/0001193125-26-220671.json","markdown":"https://secwatch.observer/filing/0001193125-26-220671.md","text":"https://secwatch.observer/filing/0001193125-26-220671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/d10320d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:23:36.871699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68ef9f455e","claim":"Donn Casale was appointed as President at ARS Pharmaceuticals, Inc..","evidence_excerpt":"appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"a8575c784e","claim":"Richard Lowenthal changed role as President at ARS Pharmaceuticals, Inc..","evidence_excerpt":"Mr. Lowenthal previously served as President.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526220671/0001193125-26-220671-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}